Table 3 Neo-adjuvant therapy
Neo-Adjuvant Therapy | Total (N = 91) | No Subsequent Adjuvant Therapy (N = 30) | Subsequent Adjuvant Therapy (N = 61) | |||
|---|---|---|---|---|---|---|
n | % | n | % | n | % | |
Neo-adj CT onlya | 66 | 72.5 | 16 | 53.3 | 50 | 82.0 |
Doxo–Cyclophos–Paclitaxel | 31 | 34.1 | 7 | 23.3 | 24 | 39.3 |
Docetaxel–Doxo–Cyclophos | 6 | 6.6 | 2 | 6.7 | 4 | 6.6 |
Doxo–Cyclophos–Docetaxel | 6 | 6.6 | 3 | 10.0 | 3 | 4.9 |
Cyclophos–Doxo–Paclitaxel | 3 | 3.3 | 0 | 0.0 | 3 | 4.9 |
Docetaxel–Cyclophos | 3 | 3.3 | 1 | 3.3 | 2 | 3.3 |
Doxo–Cyclophos | 3 | 3.3 | 1 | 3.3 | 2 | 3.3 |
Cyclophos–Doxo–Docetaxel | 2 | 2.2 | 0 | 0.0 | 2 | 3.3 |
Other treatment | 12 | 13.2 | 2 | 6.7 | 10 | 16.4 |
Neo-adj ET onlyb | 22 | 24.2 | 12 | 40.0 | 10 | 16.4 |
Anastrozole | 12 | 13.2 | 5 | 16.7 | 7 | 11.5 |
Letrozole | 4 | 4.4 | 4 | 13.3 | 0 | 0.0 |
Palbociclib–Letrozole | 2 | 2.2 | 1 | 3.3 | 1 | 1.6 |
Other treatment | 4 | 4.4 | 2 | 6.7 | 2 | 3.3 |
Neo-adj CT and ET | 3 | 3.3 | 2 | 6.7 | 1 | 1.6 |
Doxo–Cyclophos–Paclitaxel –Anastrozole | 2 | 2.2 | 1 | 3.3 | 1 | 1.6 |
Doxo–Cyclophos–Paclitaxel –Letrozole | 1 | 1.1 | 1 | 3.3 | 0 | 0.0 |